Cardiorespiratory Instability after Percutaneous Patent Ductus Arteriosus Closure: A Multicenter Cohort Study
- PMID: 38615941
- DOI: 10.1016/j.jpeds.2024.114052
Cardiorespiratory Instability after Percutaneous Patent Ductus Arteriosus Closure: A Multicenter Cohort Study
Abstract
Objective: To evaluate postprocedural clinical characteristics of preterm infants undergoing transcatheter patent ductus arteriosus (PDA) closure, including oxygenation/ventilation failure and cardiovascular compromise.
Study design: Multicenter retrospective cohort study of preterm infants who were ≤2 kg at the time of percutaneous PDA closure between August 2018 and July 2021. Indices of cardiorespiratory stability were collected pre-closure, immediately post-closure, and subsequently averaged every 4 hours for the first 24 hours post-procedure. The primary outcome was incidence of post-transcatheter cardiorespiratory syndrome: composite of hemodynamic instability (defined by systemic hypotension, systemic hypertension, or use of new inotropes/vasopressors in the first 24 hours after catheterization) and at least one of the following: (i) ventilation failure or (ii) oxygenation failure.
Results: A total of 197 patients were included with a median [IQR] age and weight at catheterization of 34 [25, 43] days and 1090 [900, 1367] grams, respectively. The primary composite outcome of post-transcatheter cardiorespiratory syndrome was reported in 46 (23.3%).
Conclusion: Post-transcatheter cardiorespiratory syndrome is characterized primarily by systemic hypertension and oxygenation failure, with a very low incidence of hypotension and need for inotropes.
Keywords: hypertension; hypotension; patent ductus arteriosus; percutaneous; post ligation cardiac syndrome; transcatheter.
Copyright © 2024 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest Dr. Backes has the following disclosures: Abbott: grant/material support for ongoing clinical trial (PIVOTAL; NCT05547165). Dr. Sathanandam has the following disclosures: Abbott: proctor, consultant, grant recipient and speaker's bureau; Medtronic: consultant and grant recipient; Cannon: consultant and grant recipient; Penumbra: speaker fee. Dr. Philip has the following disclosure: Abbott: speaker's bureau. Dr. McNamara has the following disclosures: Received honoraria from Abbott Cardiac ltd. for invited lectures; Consultant for Aspect imaging ltd. Funding: The authors have no financial relationships relevant to this article to disclose.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical